Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer’s Biomarker Testing Into Clinical Workflows

Key Takeaways

• LucentAD Complete now orderable via Tempus' clinical platform
• Tempus Next will flag Alzheimer’s care gaps for neurologists
• Blood‑based test aims to increase eligibility for approved therapies
• Integration reduces provider burden and speeds diagnostic decisions

Pulse Analysis

Alzheimer’s disease affects over 7 million Americans, yet only a fraction receive biomarker testing needed to qualify for disease‑modifying drugs. Blood‑based assays like LucentAD® Complete, powered by Quanterix’s ultra‑sensitive Simoa® technology, promise a less invasive, faster alternative to lumbar puncture or PET scans. By offering a multi‑biomarker panel that detects amyloid‑related proteins, the test can identify amyloid‑positive patients earlier, supporting clinicians in meeting clinical‑guideline thresholds for therapy initiation.

Tempus AI’s Next platform leverages artificial intelligence to scan electronic health records and flag care gaps where patients meet criteria for Alzheimer’s biomarker testing. Embedding LucentAD Complete into Tempus’ ordering workflow eliminates manual referral steps, allowing neurologists to order the test with a single click. The integration aligns with broader trends toward AI‑driven precision medicine, where data‑rich tools guide point‑of‑care decisions and reduce administrative friction, ultimately improving diagnostic confidence and patient throughput.

The partnership signals a shift in the diagnostic market toward scalable, reimbursable blood tests that can be deployed across community practices and academic centers alike. As insurers begin to recognize the clinical value of early detection, demand for such assays is likely to rise, creating new revenue streams for both Quanterix and Tempus. Moreover, the collaboration sets a precedent for future AI‑enabled diagnostic pathways, potentially extending to other neurodegenerative conditions and solidifying the role of integrated digital health platforms in modern care delivery.